Gilead Files 8-K on Financial Results & Condition

TL;DR

**Gilead just dropped an 8-K with their latest financial results, so expect some market reaction.**

AI Summary

Gilead Sciences, Inc. filed an 8-K on February 6, 2024, to report its financial results and condition, as well as to include related exhibits. This filing, under Items 2.02 and 9.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers the latest official look into Gilead's financial health, which can influence stock price movements and future investment decisions.

Why It Matters

This filing provides investors with the most current official financial information from Gilead Sciences, which is crucial for evaluating the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and does not inherently signal high risk, though the results themselves could be positive or negative.

Analyst Insight

An investor should review the full financial statements and exhibits referenced in this 8-K to understand Gilead's latest performance metrics and assess their impact on the company's valuation and future prospects.

Key Numbers

• $0.001 — par value per share (This is the nominal value assigned to each share of Gilead's Common Stock.)

Key Players & Entities

• Gilead Sciences, Inc. (company) — the registrant filing the 8-K
• February 6, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for Gilead Sciences, Inc.
• 000-19731 (dollar_amount) — Commission File No. for Gilead Sciences, Inc.
• 94-3047598 (dollar_amount) — IRS Employer Identification No. for Gilead Sciences, Inc.
• 333 Lakeside Drive, Foster City, California 94404 (company) — address of principal executive offices for Gilead Sciences, Inc.
• 650-574-3000 (dollar_amount) — telephone number for Gilead Sciences, Inc.
• $0.001 (dollar_amount) — par value per share of Common Stock
• GILD (company) — trading symbol for Gilead Sciences, Inc. Common Stock
• The Nasdaq Global Select Market (company) — exchange where Gilead Sciences, Inc. Common Stock is registered

Forward-Looking Statements

• Gilead's stock price (GILD) will react to the financial results disclosed in the full filing. (GILD) — high confidence, target: 2024-02-07

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select

Filing Documents

• gild-20240206.htm (8-K) — 32KB
• exhibit991earningspressrel.htm (EX-99.1) — 716KB
• gilead_transparentxlogoxst.jpg (GRAPHIC) — 37KB
• 0000882095-24-000003.txt ( ) — 964KB
• gild-20240206.xsd (EX-101.SCH) — 2KB
• gild-20240206_lab.xml (EX-101.LAB) — 24KB
• gild-20240206_pre.xml (EX-101.PRE) — 12KB
• gild-20240206_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 6, 2024 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles ("GAAP") and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead's operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 10, 11 and 12 of the press release filed as Exhibit 99.1 to this report. The information in Item 2.02 and Item 9.01 of this Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. Section 9 - FINANCIAL STATEMENTS AND EXHIBITS

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on February 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ ANDREW D. DICKINSON Andrew D. Dickinson Chief Financial Officer Date: February 6, 2024 Exhibit Index Exhibit Number Description 99.1 Press Release, issued by Gilead Sciences, Inc. on February 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

View Full Filing

View this 8-K filing on SEC EDGAR